By Colin Kellaher


Regeneron Pharmaceuticals and Sanofi have won expanded Food and Drug Administration approval of their arthritis drug Kevzara for certain patients with a form of the disease that impacts multiple joints at a time.

Regeneron and Sanofi on Tuesday said the new indication covers the treatment of patients weighing at least 139 pounds who have active polyarticular juvenile idiopathic arthritis.

The companies said the approval adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica.

Tarrytown, N.Y., biotechnology company Regeneron and France's Sanofi are jointly developing Kevzara as part of a collaboration that includes the blockbuster anti-inflammatory drug Dupixent.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-11-24 0735ET